product summary
Loading...
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
Galanin R2/GALR2 Antibody - BSA Free
catalog :
NLS4156
quantity :
0.05 ml
price :
409 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
immunohistochemistry, immunohistochemistry - paraffin section
more info or order :
product information
master code :
NLS4156
SKU :
NLS4156
product name :
Galanin R2/GALR2 Antibody - BSA Free
unit size :
0.05 ml
description :
The Galanin R2/GALR2 Antibody - BSA Free from Novus is a rabbit polyclonal antibody to Galanin R2/GALR2. This antibody reacts with human. The Galanin R2/GALR2 Antibody - BSA Free has been validated for the following applications: Immunohistochemistry,Immunohistochemistry-Paraffin.
target :
Galanin R2/GALR2
category :
Primary Antibodies
buffer :
PBS
clonality :
Polyclonal
concentration :
1.0 mg/ml
conjugate :
Unconjugated
host :
Rabbit
immunogen :
Synthetic 18 amino acid peptide from 7th transmembrane domain of human Galanin R2/GALR2.
isotype :
IgG
purity :
Immunogen affinity purified
species :
Human
specificity :
Human GALR2
gene symbol :
GALR2
applications :
Immunohistochemistry,Immunohistochemistry-Paraffin
USD :
409 USD
alt names :
GAL2-R, galanin receptor 2, galanin receptor type 2, GALNR2MGC125984, GALR-2, MGC125983
storage :
Keep as concentrated solution. Aliquot and store at -20C or below. Avoid multiple freeze-thaw cycles.
more info or order :
company information

Novus Biologicals
10771 E Easter Ave
Centennial, CO 80112
Centennial, CO 80112
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
related products
browse more products
questions and comments